JPRN-jRCTs031180184进行中（未招募）1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive schwannoma from Neurofibromatosis type 2
Toda Masahiro0 个研究点目标入组 20 人开始时间: 2019年3月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1) Progressive schwannoma (Neurofibromatosis 2) without surgical and radiorogical justification
- •2) announcement of a diagnosis
- •3) HLA-A*2402,A*0201,A*0206 or A*0207
- •4) Age between 12 to 79
- •5) Performance status (ECOG) of 0-2
- •6) Over 4 weeks after surgery, irradiation, or chemotherapy.
- •7) Sufficient function of important organs.
- •8) No uncontrollable pleural, peritoneal or cardiac effusion.
- •9) Expected survival time: more than 3 months. ]
- •10) preventing conception
- •11) Written informed consents are obtained.
排除标准
- •1) Uncontrollable severe infectious diseases.
- •2) Serious concomitant diseases
- •3) Adverse event of NCI-CTC grade 3 or 4.
- •4) Unable to take anything orally over 24 hours.
- •5) Active multiple cancers.
- •6) Myeloproliferative diseases such as MDS and CML.
- •7) After allogeneic hematopoietic stem cell transplantation.
- •8) Active autoimmune diseases.
- •9) Severe drug allergy
- •10) Necessity for administration of steroid or immunosuppressive drugs.
- •11) Pregnancy or lactation. Patients hope pregnancy
- •12) Psychiatric disorders.
- •13) Unhealed injury.
- •14) Judged as inappropriate for this study by doctors.
研究者
相似试验
已完成
1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive or recurrent glioblastoma.GlioblastomaJPRN-UMIN000005545Department of Neurosurgery, Keio University School of Medicine20
招募中
1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive schwannoma from Neurofibromatosis type 2eurofibromatosis type 2 with progressive schwannomaJPRN-UMIN000023565Keio university school of medicine10
招募中
1 期
VEGFR1/2 peptide vaccine for patients with primary malignant gliomaJPRN-jRCTs031180170Toda Masahiro15
招募中
1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with primary malignant gliomaMalignant gliomaJPRN-UMIN000013381Department of Neurosurgery, Keio University School of Medicine20
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6